Skip to main content
Top
Published in: Respiratory Research 1/2009

Open Access 01-12-2009 | Research

Specific mediator inhibition by the NO donors SNP and NCX 2057 in the peripheral lung: implications for allergen-induced bronchoconstriction

Authors: Anna-Karin Larsson, Magnus Bäck, Jon O Lundberg, Sven-Erik Dahlén

Published in: Respiratory Research | Issue 1/2009

Login to get access

Abstract

Background

The aim of this study was to examine potential therapeutic effect of the two NO donors NCX 2057 (3-(4-hydroxy-3-methoxyphenyl)-2-propenoic acid) 4-(nitrooxy)butyl ester) and SNP (sodium nitroprusside) on the early allergic airway response in the peripheral lung.

Methods

The experiments were performed in guinea pig lung parenchyma (GPLP) derived from ovalbumin (OVA) sensitized guinea pigs. The effects of NCX 2057 and SNP were evaluated by contractile responses and mediator release during OVA challenge. The generation of nitrite and nitrate was assessed by chemiluminescence. Statistical analysis was evaluated by ANOVA.

Results

Cumulatively increasing concentrations of OVA (1–10,000 ng/ml) induced concentration-dependent contractions of the GPLP that were reduced by NCX 2057 (100 μM, p < 0.001) and SNP (100 μM, p < 0.05). Antigen-induced eicosanoid release was decreased by NCX 2057 (100 μM, p < 0.001) but not by SNP (100 μM), whereas the release of histamine was reduced by SNP (100 μM, p < 0.001) but not by NCX 2057 (100 μM). In addition, NCX 2057 (0.1–100 μM), but not SNP (0.1–100 μM), relaxed leukotriene D4 (10 nM) precontracted GPLP (p < 0.01). The guanylyl cyclase inhibitor ODQ had no effect on the NCX 2057 mediated relaxation. SNP released significantly less nitrite than NCX 2057.

Conclusion

Although both SNP and NCX 2057 reduced the release of pro-inflammatory mediators, their profiles were distinctly different. Furthermore, NCX 2057 also induced smooth muscle dilation in the GPLP. The findings point to specific anti-inflammatory effects of different NO donors in the peripheral lung tissue.
Literature
1.
go back to reference Rastaldo R, Pagliaro P, Cappello S, Penna C, Mancardi D, Westerhof N, Losano G: Nitric oxide and cardiac function. Life Sci 2007, 81:779–93.CrossRefPubMed Rastaldo R, Pagliaro P, Cappello S, Penna C, Mancardi D, Westerhof N, Losano G: Nitric oxide and cardiac function. Life Sci 2007, 81:779–93.CrossRefPubMed
2.
go back to reference Gaston B, Drazen JM, Loscalzo J, Stamler JS: The biology of nitrogen oxides in the airways. Am J Respir Crit Care Med 1994, 149:538–51.CrossRefPubMed Gaston B, Drazen JM, Loscalzo J, Stamler JS: The biology of nitrogen oxides in the airways. Am J Respir Crit Care Med 1994, 149:538–51.CrossRefPubMed
3.
go back to reference Hogman M, Frostell CG, Hedenstrom H, Hedenstierna G: Inhalation of nitric oxide modulates adult human bronchial tone. Am Rev Respir Dis 1993, 148:1474–8.CrossRefPubMed Hogman M, Frostell CG, Hedenstrom H, Hedenstierna G: Inhalation of nitric oxide modulates adult human bronchial tone. Am Rev Respir Dis 1993, 148:1474–8.CrossRefPubMed
4.
go back to reference Barrington KJ, Finer NN: Inhaled nitric oxide for respiratory failure in preterm infants. Cochrane Database Syst Rev 2007, CD000509. Barrington KJ, Finer NN: Inhaled nitric oxide for respiratory failure in preterm infants. Cochrane Database Syst Rev 2007, CD000509.
5.
go back to reference Lordan JL, Holgate ST: H1-antihistamines in asthma. Clin Allergy Immunol 2002, 17:221–48.PubMed Lordan JL, Holgate ST: H1-antihistamines in asthma. Clin Allergy Immunol 2002, 17:221–48.PubMed
6.
go back to reference Wenzel SE, Westcott JY, Larsen GL: Bronchoalveolar lavage fluid mediator levels 5 minutes after allergen challenge in atopic subjects with asthma: relationship to the development of late asthmatic responses. J Allergy Clin Immunol 1991, 87:540–8.CrossRefPubMed Wenzel SE, Westcott JY, Larsen GL: Bronchoalveolar lavage fluid mediator levels 5 minutes after allergen challenge in atopic subjects with asthma: relationship to the development of late asthmatic responses. J Allergy Clin Immunol 1991, 87:540–8.CrossRefPubMed
7.
go back to reference Rolin S, Masereel B, Dogne JM: Prostanoids as pharmacological targets in COPD and asthma. Eur J Pharmacol 2006, 533:89–100.CrossRefPubMed Rolin S, Masereel B, Dogne JM: Prostanoids as pharmacological targets in COPD and asthma. Eur J Pharmacol 2006, 533:89–100.CrossRefPubMed
8.
go back to reference Dahlen SE: Treatment of asthma with antileukotrienes: first line or last resort therapy? Eur J Pharmacol 2006, 533:40–56.CrossRefPubMed Dahlen SE: Treatment of asthma with antileukotrienes: first line or last resort therapy? Eur J Pharmacol 2006, 533:40–56.CrossRefPubMed
9.
go back to reference Gilchrist M, Savoie M, Nohara O, Wills FL, Wallace JL, Befus AD: Nitric oxide synthase and nitric oxide production in in vivo-derived mast cells. J Leukoc Biol 2002, 71:618–24.PubMed Gilchrist M, Savoie M, Nohara O, Wills FL, Wallace JL, Befus AD: Nitric oxide synthase and nitric oxide production in in vivo-derived mast cells. J Leukoc Biol 2002, 71:618–24.PubMed
10.
go back to reference Dean Befus YS, Moon TC, Munoz S, Befus AD: Role of nitric oxide in mast cells: controversies, current knowledge, and future applications. Immunol Res 2005, 33:223–39.CrossRefPubMed Dean Befus YS, Moon TC, Munoz S, Befus AD: Role of nitric oxide in mast cells: controversies, current knowledge, and future applications. Immunol Res 2005, 33:223–39.CrossRefPubMed
11.
go back to reference Coffey MJ, Phare SM, Peters-Golden M: Prolonged exposure to lipopolysaccharide inhibits macrophage 5-lipoxygenase metabolism via induction of nitric oxide synthesis. J Immunol 2000, 165:3592–8.CrossRefPubMed Coffey MJ, Phare SM, Peters-Golden M: Prolonged exposure to lipopolysaccharide inhibits macrophage 5-lipoxygenase metabolism via induction of nitric oxide synthesis. J Immunol 2000, 165:3592–8.CrossRefPubMed
12.
go back to reference Masini E, Salvemini D, Pistelli A, Mannaioni PF, Vane JR: Rat mast cells synthesize a nitric oxide like-factor which modulates the release of histamine. Agents Actions 1991, 33:61–3.CrossRefPubMed Masini E, Salvemini D, Pistelli A, Mannaioni PF, Vane JR: Rat mast cells synthesize a nitric oxide like-factor which modulates the release of histamine. Agents Actions 1991, 33:61–3.CrossRefPubMed
13.
go back to reference Gilchrist M, McCauley SD, Befus AD: Expression, localization, and regulation of NOS in human mast cell lines: effects on leukotriene production. Blood 2004, 104:462–9.CrossRefPubMed Gilchrist M, McCauley SD, Befus AD: Expression, localization, and regulation of NOS in human mast cell lines: effects on leukotriene production. Blood 2004, 104:462–9.CrossRefPubMed
14.
go back to reference Larsson AK, Back M, Hjoberg J, Dahlen SE: Inhibition of nitric-oxide synthase enhances antigen-induced contractions and increases release of cysteinyl-leukotrienes in guinea pig lung parenchyma: nitric oxide as a protective factor. J Pharmacol Exp Ther 2005, 315:458–65.CrossRefPubMed Larsson AK, Back M, Hjoberg J, Dahlen SE: Inhibition of nitric-oxide synthase enhances antigen-induced contractions and increases release of cysteinyl-leukotrienes in guinea pig lung parenchyma: nitric oxide as a protective factor. J Pharmacol Exp Ther 2005, 315:458–65.CrossRefPubMed
15.
go back to reference Larsson AK, Fumagalli F, DiGennaro A, Andersson M, Lundberg J, Edenius C, Govoni M, Monopoli A, Sala A, Dahlen SE, Folco GC: A new class of nitric oxide-releasing derivatives of cetirizine; pharmacological profile in vascular and airway smooth muscle preparations. Br J Pharmacol 2007, 151:35–44.CrossRefPubMedPubMedCentral Larsson AK, Fumagalli F, DiGennaro A, Andersson M, Lundberg J, Edenius C, Govoni M, Monopoli A, Sala A, Dahlen SE, Folco GC: A new class of nitric oxide-releasing derivatives of cetirizine; pharmacological profile in vascular and airway smooth muscle preparations. Br J Pharmacol 2007, 151:35–44.CrossRefPubMedPubMedCentral
16.
go back to reference Fiorucci S, Antonelli E: NO-NSAIDs: from inflammatory mediators to clinical readouts. Inflamm Allergy Drug Targets 2006, 5:121–31.CrossRefPubMed Fiorucci S, Antonelli E: NO-NSAIDs: from inflammatory mediators to clinical readouts. Inflamm Allergy Drug Targets 2006, 5:121–31.CrossRefPubMed
17.
go back to reference Wenk GL, McGann-Gramling K, Hauss-Wegrzyniak B, Ronchetti D, Maucci R, Rosi S, Gasparini L, Ongini E: Attenuation of chronic neuroinflammation by a nitric oxide-releasing derivative of the antioxidant ferulic acid. J Neurochem 2004, 89:484–93.CrossRefPubMed Wenk GL, McGann-Gramling K, Hauss-Wegrzyniak B, Ronchetti D, Maucci R, Rosi S, Gasparini L, Ongini E: Attenuation of chronic neuroinflammation by a nitric oxide-releasing derivative of the antioxidant ferulic acid. J Neurochem 2004, 89:484–93.CrossRefPubMed
19.
go back to reference Shin DD, Brandimarte F, De Luca L, Sabbah HN, Fonarow GC, Filippatos G, Komajda M, Gheorghiade M: Review of current and investigational pharmacologic agents for acute heart failure syndromes. Am J Cardiol 2007, 99:4A-23A.CrossRefPubMed Shin DD, Brandimarte F, De Luca L, Sabbah HN, Fonarow GC, Filippatos G, Komajda M, Gheorghiade M: Review of current and investigational pharmacologic agents for acute heart failure syndromes. Am J Cardiol 2007, 99:4A-23A.CrossRefPubMed
20.
go back to reference Jonsson EW, Dahlen SE: Interactions between leukotrienes and histamine in the anaphylactic contraction of guinea pig lung parenchyma. J Pharmacol Exp Ther 1994, 271:615–23.PubMed Jonsson EW, Dahlen SE: Interactions between leukotrienes and histamine in the anaphylactic contraction of guinea pig lung parenchyma. J Pharmacol Exp Ther 1994, 271:615–23.PubMed
21.
go back to reference Ressmeyer AR, Larsson AK, Vollmer E, Dahlen SE, Uhlig S, Martin C: Characterisation of guinea pig precision-cut lung slices: comparison with human tissues. Eur Respir J 2006, 28:603–11.CrossRefPubMed Ressmeyer AR, Larsson AK, Vollmer E, Dahlen SE, Uhlig S, Martin C: Characterisation of guinea pig precision-cut lung slices: comparison with human tissues. Eur Respir J 2006, 28:603–11.CrossRefPubMed
22.
go back to reference Sundstrom E, Lastbom L, Ryrfeldt A, Dahlen SE: Interactions among three classes of mediators explain antigen-induced bronchoconstriction in the isolated perfused and ventilated guinea pig lung. J Pharmacol Exp Ther 2003, 307:408–18.CrossRefPubMed Sundstrom E, Lastbom L, Ryrfeldt A, Dahlen SE: Interactions among three classes of mediators explain antigen-induced bronchoconstriction in the isolated perfused and ventilated guinea pig lung. J Pharmacol Exp Ther 2003, 307:408–18.CrossRefPubMed
23.
go back to reference Shore PA, Burkhalter A, Cohn VH Jr: A method for the fluorometric assay of histamine in tissues. J Pharmacol Exp Ther 1959, 127:182–6.PubMed Shore PA, Burkhalter A, Cohn VH Jr: A method for the fluorometric assay of histamine in tissues. J Pharmacol Exp Ther 1959, 127:182–6.PubMed
24.
go back to reference Bergendorff A, Uvnas B: Storage of 5-hydroxytryptamine in rat mast cells. Evidence for an ionic binding to carboxyl groups in a granule heparin-protein complex. Acta Physiol Scand 1972, 84:320–31.CrossRefPubMed Bergendorff A, Uvnas B: Storage of 5-hydroxytryptamine in rat mast cells. Evidence for an ionic binding to carboxyl groups in a granule heparin-protein complex. Acta Physiol Scand 1972, 84:320–31.CrossRefPubMed
25.
go back to reference Lundberg JO, Govoni M: Inorganic nitrate is a possible source for systemic generation of nitric oxide. Free Radic Biol Med 2004, 37:395–400.CrossRefPubMed Lundberg JO, Govoni M: Inorganic nitrate is a possible source for systemic generation of nitric oxide. Free Radic Biol Med 2004, 37:395–400.CrossRefPubMed
26.
go back to reference Kanaoka Y, Boyce JA: Cysteinyl leukotrienes and their receptors: cellular distribution and function in immune and inflammatory responses. J Immunol 2004, 173:1503–10.CrossRefPubMed Kanaoka Y, Boyce JA: Cysteinyl leukotrienes and their receptors: cellular distribution and function in immune and inflammatory responses. J Immunol 2004, 173:1503–10.CrossRefPubMed
28.
go back to reference LJ Roberts 2nd, Sweetman BJ, Lewis RA, Austen KF, Oates JA: Increased production of prostaglandin D2 in patients with systemic mastocytosis. N Engl J Med 1980, 303:1400–4.CrossRef LJ Roberts 2nd, Sweetman BJ, Lewis RA, Austen KF, Oates JA: Increased production of prostaglandin D2 in patients with systemic mastocytosis. N Engl J Med 1980, 303:1400–4.CrossRef
29.
go back to reference Dahlen SE, Hedqvist P, Westlund P, Granstrom E, Hammarstrom S, Lindgren JA, Radmark O: Mechanisms of leukotriene-induced contractions of guinea pig airways: leukotriene C4 has a potent direct action whereas leukotriene B4 acts indirectly. Acta Physiol Scand 1983, 118:393–403.CrossRefPubMed Dahlen SE, Hedqvist P, Westlund P, Granstrom E, Hammarstrom S, Lindgren JA, Radmark O: Mechanisms of leukotriene-induced contractions of guinea pig airways: leukotriene C4 has a potent direct action whereas leukotriene B4 acts indirectly. Acta Physiol Scand 1983, 118:393–403.CrossRefPubMed
30.
go back to reference Lancaster JR Jr, Langrehr JM, Bergonia HA, Murase N, Simmons RL, Hoffman RA: EPR detection of heme and nonheme iron-containing protein nitrosylation by nitric oxide during rejection of rat heart allograft. J Biol Chem 1992, 267:10994–8.PubMed Lancaster JR Jr, Langrehr JM, Bergonia HA, Murase N, Simmons RL, Hoffman RA: EPR detection of heme and nonheme iron-containing protein nitrosylation by nitric oxide during rejection of rat heart allograft. J Biol Chem 1992, 267:10994–8.PubMed
31.
go back to reference Forsythe P, Befus AD: Inhibition of calpain is a component of nitric oxide-induced down-regulation of human mast cell adhesion. J Immunol 2003, 170:287–93.CrossRefPubMed Forsythe P, Befus AD: Inhibition of calpain is a component of nitric oxide-induced down-regulation of human mast cell adhesion. J Immunol 2003, 170:287–93.CrossRefPubMed
32.
go back to reference Lim SY, Raftery M, Cai H, Hsu K, Yan WX, Hseih HL, Watts RN, Richardson D, Thomas S, Perry M, Geczy CL: S-nitrosylated S100A8: novel anti-inflammatory properties. J Immunol 2008, 181:5627–36.CrossRefPubMed Lim SY, Raftery M, Cai H, Hsu K, Yan WX, Hseih HL, Watts RN, Richardson D, Thomas S, Perry M, Geczy CL: S-nitrosylated S100A8: novel anti-inflammatory properties. J Immunol 2008, 181:5627–36.CrossRefPubMed
33.
go back to reference Que LG, Liu L, Yan Y, Whitehead GS, Gavett SH, Schwartz DA, Stamler JS: Protection from experimental asthma by an endogenous bronchodilator. Science 2005, 308:1618–21.CrossRefPubMedPubMedCentral Que LG, Liu L, Yan Y, Whitehead GS, Gavett SH, Schwartz DA, Stamler JS: Protection from experimental asthma by an endogenous bronchodilator. Science 2005, 308:1618–21.CrossRefPubMedPubMedCentral
34.
go back to reference Coffey MJ, Coles B, O'Donnell VB: Interactions of nitric oxide-derived reactive nitrogen species with peroxidases and lipoxygenases. Free Radic Res 2001, 35:447–64.CrossRefPubMed Coffey MJ, Coles B, O'Donnell VB: Interactions of nitric oxide-derived reactive nitrogen species with peroxidases and lipoxygenases. Free Radic Res 2001, 35:447–64.CrossRefPubMed
35.
go back to reference Goodwin DC, Landino LM, Marnett LJ: Effects of nitric oxide and nitric oxide-derived species on prostaglandin endoperoxide synthase and prostaglandin biosynthesis. Faseb J 1999, 13:1121–36.PubMed Goodwin DC, Landino LM, Marnett LJ: Effects of nitric oxide and nitric oxide-derived species on prostaglandin endoperoxide synthase and prostaglandin biosynthesis. Faseb J 1999, 13:1121–36.PubMed
36.
go back to reference Hosoda A, Ozaki Y, Kashiwada A, Mutoh M, Wakabayashi K, Mizuno K, Nomura E, Taniguchi H: Syntheses of ferulic acid derivatives and their suppressive effects on cyclooxygenase-2 promoter activity. Bioorg Med Chem 2002, 10:1189–96.CrossRefPubMed Hosoda A, Ozaki Y, Kashiwada A, Mutoh M, Wakabayashi K, Mizuno K, Nomura E, Taniguchi H: Syntheses of ferulic acid derivatives and their suppressive effects on cyclooxygenase-2 promoter activity. Bioorg Med Chem 2002, 10:1189–96.CrossRefPubMed
37.
go back to reference Greiff L, Andersson M, Svensson C, Nilsson M, Erjefalt I, Erjefalt JS, Persson CG: Topical nitroprusside may reduce histamine-induced plasma exudation in human nasal airways. Allergy 1995, 50:593–7.CrossRefPubMed Greiff L, Andersson M, Svensson C, Nilsson M, Erjefalt I, Erjefalt JS, Persson CG: Topical nitroprusside may reduce histamine-induced plasma exudation in human nasal airways. Allergy 1995, 50:593–7.CrossRefPubMed
38.
go back to reference Masini E, Di Bello MG, Pistelli A, Raspanti S, Gambassi F, Mugnai L, Lupini M, Mannaioni PF: Generation of nitric oxide from nitrovasodilators modulates the release of histamine from mast cells. J Physiol Pharmacol 1994, 45:41–53.PubMed Masini E, Di Bello MG, Pistelli A, Raspanti S, Gambassi F, Mugnai L, Lupini M, Mannaioni PF: Generation of nitric oxide from nitrovasodilators modulates the release of histamine from mast cells. J Physiol Pharmacol 1994, 45:41–53.PubMed
39.
go back to reference Mannaioni PF, Bello MG, Di Bello MG, Mirabella C, Gai P, Schunack W, Masini E: Interaction between histamine and nitric oxide in rat mast cells and in isolated guinea pig hearts. Int Arch Allergy Immunol 1997, 113:297–9.CrossRefPubMed Mannaioni PF, Bello MG, Di Bello MG, Mirabella C, Gai P, Schunack W, Masini E: Interaction between histamine and nitric oxide in rat mast cells and in isolated guinea pig hearts. Int Arch Allergy Immunol 1997, 113:297–9.CrossRefPubMed
40.
go back to reference Branka JE, Vallette G, Jarry A, Laboisse CL: Stimulation of mucin exocytosis from human epithelial cells by nitric oxide: evidence for a cGMP-dependent and a cGMP-independent pathway. Biochem J 1997,323(Pt 2):521–4.CrossRefPubMedPubMedCentral Branka JE, Vallette G, Jarry A, Laboisse CL: Stimulation of mucin exocytosis from human epithelial cells by nitric oxide: evidence for a cGMP-dependent and a cGMP-independent pathway. Biochem J 1997,323(Pt 2):521–4.CrossRefPubMedPubMedCentral
41.
go back to reference Jansen A, Drazen J, Osborne JA, Brown R, Loscalzo J, Stamler JS: The relaxant properties in guinea pig airways of S-nitrosothiols. J Pharmacol Exp Ther 1992, 261:154–60.PubMed Jansen A, Drazen J, Osborne JA, Brown R, Loscalzo J, Stamler JS: The relaxant properties in guinea pig airways of S-nitrosothiols. J Pharmacol Exp Ther 1992, 261:154–60.PubMed
42.
go back to reference Gaston B, Drazen JM, Jansen A, Sugarbaker DA, Loscalzo J, Richards W, Stamler JS: Relaxation of human bronchial smooth muscle by S-nitrosothiols in vitro. J Pharmacol Exp Ther 1994, 268:978–84.PubMed Gaston B, Drazen JM, Jansen A, Sugarbaker DA, Loscalzo J, Richards W, Stamler JS: Relaxation of human bronchial smooth muscle by S-nitrosothiols in vitro. J Pharmacol Exp Ther 1994, 268:978–84.PubMed
43.
go back to reference Feelisch M: The use of nitric oxide donors in pharmacological studies. Naunyn Schmiedebergs Arch Pharmacol 1998, 358:113–22.CrossRefPubMed Feelisch M: The use of nitric oxide donors in pharmacological studies. Naunyn Schmiedebergs Arch Pharmacol 1998, 358:113–22.CrossRefPubMed
44.
go back to reference Govoni M, Casagrande S, Maucci R, Chiroli V, Tocchetti P: In vitro metabolism of (nitrooxy)butyl ester nitric oxide-releasing compounds: comparison with glyceryl trinitrate. J Pharmacol Exp Ther 2006, 317:752–61.CrossRefPubMed Govoni M, Casagrande S, Maucci R, Chiroli V, Tocchetti P: In vitro metabolism of (nitrooxy)butyl ester nitric oxide-releasing compounds: comparison with glyceryl trinitrate. J Pharmacol Exp Ther 2006, 317:752–61.CrossRefPubMed
Metadata
Title
Specific mediator inhibition by the NO donors SNP and NCX 2057 in the peripheral lung: implications for allergen-induced bronchoconstriction
Authors
Anna-Karin Larsson
Magnus Bäck
Jon O Lundberg
Sven-Erik Dahlén
Publication date
01-12-2009
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2009
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/1465-9921-10-46

Other articles of this Issue 1/2009

Respiratory Research 1/2009 Go to the issue